Laboratory monitoring of which of the following is desirable with low molecular weight heparin therapy in a patient with renal failure?
**Core Concept**
Low molecular weight heparin (LMWH) is a type of anticoagulant that is commonly used to prevent and treat thromboembolic disorders. However, its effectiveness and safety in patients with renal failure are a concern due to the potential for accumulation of the drug and its metabolites, leading to increased risk of bleeding.
**Why the Correct Answer is Right**
Monitoring of anti-factor Xa levels is essential in patients with renal failure receiving LMWH therapy. This is because LMWH is primarily eliminated by the kidneys, and in patients with renal impairment, the clearance of LMWH is reduced, leading to increased levels of the drug and its active metabolites. Elevated anti-factor Xa levels can increase the risk of bleeding, and monitoring can help guide dose adjustments to maintain therapeutic levels while minimizing the risk of adverse effects.
**Why Each Wrong Option is Incorrect**
**Option A:** Monitoring of activated partial thromboplastin time (aPTT) is not recommended for LMWH therapy, as it is not a sensitive measure of LMWH's anticoagulant activity.
**Option B:** Monitoring of prothrombin time (PT) is not necessary for LMWH therapy, as LMWH does not affect the extrinsic coagulation pathway.
**Option C:** Monitoring of platelet count is not a reliable indicator of the anticoagulant effect of LMWH, as LMWH does not cause significant thrombocytopenia.
**Clinical Pearl / High-Yield Fact**
In patients with renal failure, LMWH doses should be adjusted based on anti-factor Xa levels, and monitoring should be performed at least once a week to ensure therapeutic levels are maintained while minimizing the risk of bleeding.
**Correct Answer:** C.